All In Biotech

NDA 205832 · Boehringer Ingelheim

Ofev

Nintedanib Esylate · Oral

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Oct 15, 2014

Approved uses

3

Original approval plus efficacy supplements

Registered trials

170

30 Phase 3, 10 recruiting

FAERS reports

32,515

22,042 serious, 6,449 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 20, 2025.

OFEV is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) ( 1.3 ) 1.1 Idiopathic Pulmonary Fibrosis OFEV is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype OFEV is indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype [see Clinical Studies (14.2) ] . 1.3 Systemic Sclerosis-Associated Interstitial Lung Disease OFEV is indicated to slow the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Mechanism: Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, colony stimulating factor 1 receptor (CSF1R), and Fms-like tyrosine kinase-3 (FLT-3). These kinases except for FLT-3 have been implicated in pathogenesis of interstitial lung diseases (ILD). Nintedanib binds competitively to the adenosine triphosphate (ATP) binding...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 9, 2020 Supplement 13 · Efficacy · priority review Breakthrough therapyLabelLetterReview
  • Sep 6, 2019 Supplement 12 · Efficacy · priority review OrphanLetterLabelReview
  • Oct 15, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
2 products under this application
  • OFEV · NINTEDANIB ESYLATE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • OFEV · NINTEDANIB ESYLATE EQ 100MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nintedanib Esylate" as an intervention, any sponsor and status, largest first.

All 170 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea10,539
  • nausea4,818
  • dyspnoea4,179
  • cough3,397
  • death3,386
  • decreased appetite3,188
  • weight decreased3,173
  • fatigue3,033
  • vomiting2,828
  • idiopathic pulmonary fibrosis2,209
  • headache2,071
  • constipation2,053

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20133
201436
2015960
20161,298
20171,463
20181,924
20192,057
20202,461
20213,012
20223,745
20233,790
20244,276
20253,898
20263,591

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ofev (Nintedanib Esylate)

2024 spending

$2.09B

Beneficiaries

23,929

161,717 claims

Per beneficiary

$87,191

$216.45 per unit

View as table
YearSpending
2020$1,157,563,828
2021$1,495,198,249
2022$1,762,963,783
2023$1,837,061,150
2024$2,086,398,979

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.